<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
	<link type="text/css" rel="stylesheet" href="page.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
	<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.0.7/css/all.css">
	<link rel="stylesheet" type="text/css"
	  media="screen and (max-device-width: 480px)"
	  href="mobile.css" />
	<link href="https://use.fontawesome.com/releases/v5.0.7/css/brands.css" rel="stylesheet">
	<link href="https://use.fontawesome.com/releases/v5.0.7/css/solid.css" rel="stylesheet">
	<script src="https://use.edgefonts.net/source-sans-pro:n4,i4,n6.js"></script>
    <title>References</title>
</head>
<body>
<div id="content">
<h1>Chemical Biology Graduate Program Poster Session</h1>
<h3>11/18/2020</h3>
<a href="Poster_Presentations/Images/2020_Rotation_01_Nomura_Lab.png">
    <img src="Poster_Presentations/Images/2020_Rotation_01_Nomura_Lab_Title.png" class="img-top" alt="Card Back" width="80%">
</a>

<table id="references">
    <tr>
        <td>
            1)
        </td>
        <td>
            Nomura, D. K.
            "Our Research."
            <i>Nomura Research Group Website</i>, <b>2020</b>.
            <a href="https://nomuraresearchgroup.com/research/"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            2)
        </td>
        <td>
            Crews, C. M.
            Targeting the Undruggable Proteome: The Small Molecules of My Dreams
            <i>Chemistry & Biology, Elsevier BV</i>, <b>2010</b>, <i>17</i>, 551-555.
            <a href="https://doi.org/10.1016/j.chembiol.2010.05.011"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            3)
        </td>
        <td>
            Millipore-Sigma.
            "Proteomic Ligandability Assessment."
            <i>Merck KGaA, Darmstadt, Germany</i>, <b>2020</b>.
            <a href="https://www.sigmaaldrich.com/technical-documents/articles/technology-spotlights/ligandability.html">
                <i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            4)
        </td>
        <td>
            Roberts, A. M.; Ward, C. C. & Nomura, D. K.
            "Activity-based protein profiling for mapping and pharmacologically interrogating
            proteome-wide ligandable hotspots."
            <i>Current Opinion in Biotechnology, Elsevier BV</i>, <b>2017</b>, <i>43</i>, 25-33.
            <a href="https://doi.org/10.1016/j.copbio.2016.08.003"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            5)
        </td>
        <td>
            Niphakis, M. J. & Cravatt, B. F.
            "Enzyme Inhibitor Discovery by Activity-Based Protein Profiling."
            <i>Annual Review of Biochemistry, Annual Reviews</i>, <b>2014</b>, <i>83</i>, 341-377.
            <a href="https://doi.org/10.1146/annurev-biochem-060713-035708"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            6)
        </td>
        <td>
            Bauer, U. & Breeze, A. L.
            "'Ligandability' of Drug Targets: Assessment of Chemical Tractability via Experimental and <i>In
            Silico</i> Approaches."
            <i>Wiley</i>, <b>2016</b>, 35-62.
            <a href="https://doi.org/10.1002/9783527677047.ch03"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            7)
        </td>
        <td>
            Backus, K. M. et al.
            "Proteome-wide covalent ligand discovery in native biological systems."
            <i>Nature, Springer Science and Business Media LLC</i>, <b>2016</b>, <i>534</i>, 570-574.
            <a href="https://doi.org/10.1038/nature18002"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            8)
        </td>
        <td>
            Jin, Z. et al.
            "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors."
            <i>Nature, Springer Science and Business Media LLC</i>, <b>2020</b>, <i>582</i>, 289-293.
            <a href="https://doi.org/10.1038/s41586-020-2223-y"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            9)
        </td>
        <td>
            Pillaiyar, T. et al.
            "An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors:
            Peptidomimetics and Small Molecule Chemotherapy."
            <i>Journal of Medicinal Chemistry, American Chemical Society (ACS)</i>, <b>2016</b>, <i>5</i>, 6595-6628.
            <a href="https://doi.org/10.1021/acs.jmedchem.5b01461"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            10)
        </td>
        <td>
            Fan, K. et al.
            "Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus
            3C-like Proteinase."
            <i>Journal of Biological Chemistry, American Society for Biochemistry & Molecular Biology (ASBMB)</i>,
            <b>2003</b>, <i>279</i>, 1637-1642.
            <a href="https://doi.org/10.1074/jbc.M310875200"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            11)
        </td>
        <td>
            Hoch, D. G.; Abegg, D. & Adibekian, A.
            "Cysteine-reactive probes and their use in chemical proteomics."
            <i>Chemical Communications, Royal Society of Chemistry (RSC)</i>, <b>2018</b>, <i>54</i>, 4501-4512.
            <a href="https://doi.org/10.1039/C8CC01485J"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            12)
        </td>
        <td>
            Nomura, D. K.
            "Discovering Coronavirus Main Protease Inhibitors."
            <i>Unpublished</i>,
            <b>2020</b>.
            <a href=""><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
      <td>
            13)
      </td>
      <td>
          Behan, F. M. et al.
          "Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens."
          <i>Nature, Springer Science and Business Media LLC</i>, <b>2019</b>, <i>568</i>, 511-516.
          <a href="https://doi.org/10.1038/s41586-019-1103-9"><i class="fas fa-link"></i></a>
      </td>
  </tr>
    <tr>
      <td>
            14)
      </td>
      <td>
          Behan, F. M.; Iorio, F.; Picco, G.; Gonçalves, E.; Beaver, C. M.; Migliardi, G.; Santos, R.; Rao, Y.;
          Sassi, F.; Pinnelli, M.; Ansari, R.; Harper, S.; Jackson, D. A.; McRae, R.; Pooley, R.; Wilkinson, P.;
          van der Meer, D.; Dow, D.; Buser-Doepner, C.; Bertotti, A.; Trusolino, L.; Stronach, E. A.;
          Saez-Rodriguez, J.; Yusa, K. & Garnett, M. J.<br>
          "Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens."<br>
          <i>Nature, Springer Science and Business Media LLC</i>, <b>2019</b>, <i>568</i>, 511-516.
          <a href="https://doi.org/10.1038/s41586-019-1103-9"><i class="fas fa-link"></i></a>
      </td>
  </tr>
    <tr>
        <td>
            15)
        </td>
        <td>
            Lazo, J. S. & Sharlow, E. R.
            "Drugging Undruggable Molecular Cancer Targets."
            <i>Annual Review of Pharmacology and Toxicology, Annual Reviews</i>, <b>2016</b>, <i>56</i>, 23-40.
            <a href="https://doi.org/10.1146/annurev-pharmtox-010715-103440"><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            16)
        </td>
        <td>
            Verdine, G. L. & Walensky, L. D.
            "The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family
            Members."
            <i>Clinical Cancer Research, American Association for Cancer Research (AACR)</i>, <b>2007</b>, <i>13</i>,
            7264-7270.
            <a href="https://doi.org/10.1158/1078-0432.ccr-07-2184"><i class="fas fa-link"></i></a>
        </td>
    </tr>


    <tr>
        <td>
            17)
        </td>
        <td>
            Koehler, A. N.
            "A complex task? Direct modulation of transcription factors with small molecules."
            <i>Current Opinion in Chemical Biology, Elsevier BV</i>, <b>2010</b>, <i>14</i>, 331-340.
            <a href=""><i class="fas fa-link"></i></a>
        </td>
    </tr>
    <tr>
        <td>
            18)
        </td>
        <td>
            Bushweller, J. H.
            "Targeting transcription factors in cancer — from undruggable to reality."
            <i>Nature Reviews Cancer, Springer Science and Business Media LLC</i>, <b>2019</b>, <i>19</i>, 611-624.
            <a href=""><i class="fas fa-link"></i></a>
        </td>
    </tr>
  <tr>
    <td>
        19)
    </td>
    <td>
        Ward, C. C. et al.
        "Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications."
        <i>ACS Chemical Biology, American Chemical Society (ACS)</i>, <b>2019</b>, <i>14</i>, 2430-2440.
        <a href="https://doi.org/10.1021/acschembio.8b01083"><i class="fas fa-link"></i></a>
    </td>
  </tr>
</table>
<br><br><br><br><br><br><br><br><br><br><br><br>
</div>
</body>
</html>